Angiogenic potential of prostate carcinoma cells overexpressing bcl-2

Journal of the National Cancer Institute

Volumn 93, Issue 3, 2001, Pages 208-213

  Fernandez, Antonio ^a   Udagawa, Taturo ^a   Schwesinger, Catherine ^a   Beecken, Wolf Dietrich ^a   Achilles Gerte, Eike ^a   McDonnell, Timothy J ^b   D'Amato, Robert J ^a,b,c  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; COMPLEMENTARY DNA; FUMAGILLOL CHLOROACETYLCARBAMATE; MITOMYCIN C; OXYGEN; PROTEIN BCL 2; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD VESSEL; CANCER CELL CULTURE; CANCER TRANSPLANTATION; CARCINOGENESIS; CARCINOMA CELL; CONTROL SYSTEM; CONTROLLED STUDY; CORNEA; DENSITY; EXPOSURE; GENE OVEREXPRESSION; GENETIC ANALYSIS; GENETIC TRANSFECTION; GROWTH RATE; HUMAN; HUMAN CELL; HYPOTHESIS; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; METHODOLOGY; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROSTATE CARCINOMA; REGULATORY MECHANISM; STATISTICAL ANALYSIS; STIMULUS; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

EID: 0035819518     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/93.3.208     Document Type: Article

References (30)

1. The hallmarks of cancer
2. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
3. Oncogenes and cell proliferation
4. Mechanisms of apoptosis avoidance in cancer
5. The histological structure of some human lung cancers and the possible implications for radiotherapy
6. Determinants of tumor blood flow: A review
7. Induction of apoptosis as well as necrosis by hypoxia and predominant prevention of apoptosis by Bcl-2 and Bcl-XL
8. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
9. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype
10. P53-dependent apoptosis suppresses tumor growth and progression in vivo
11. p53, cell cycle control and apoptosis: Implications for cancer
12. Expression of the proto-oncogene blc-2 in the prostate and its association with emergence of androgen-independent prostate cancer
13. Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18)
14. Synergistic enhancement of resistance to cisplatin in human bladder cancer cells by overexpression of mutant type p53 and Bcl-2
15. bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lympho-proliferation
16. bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes
17. Molecular characterization of mitochondrial apoptosis-inducing factor
18. Mitochondrial control of nuclear apoptosis
19. Bcl-2 inhibits p53 nuclear import following DNA damage
20. Resistance to radiation-induced apoptosis in Bcl-2-expressing cells is reversed by depleting cellular thiols
21. Regulation of lipid signaling pathways for cell survival and apoptosis by bcl-2 in prostate carcinoma cells
22. Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53
23. Tumor-induced neovascularization in the mouse eye
24. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia
25. A 24-base pair sequence 3′ to the erythropoietin gene contains a hypoxia-responsive transcriptional enhancer
26. Molecular correlates of bcl-2-enhanced growth following androgen-ablation in prostate carcinoma cells in vivo
27. Bcl-2 over-expression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer
28. Approaches to the treatment of patients with hormone-sensitive prostate cancer
29. Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides
30. Targeting bcl-2 gene to delay androgen independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 deoxynucleotides